| Old Articles: <Older 1171-1180 Newer> |
|---|
 |
BusinessWeek
May 17, 2004
Gene G. Marcial |
Take a Closer Look At Eye-Opening VISX One super highflier last year was VISX, the top developer of technologies for laser vision correction, and may be poised for a second wave as some pros are arguing it could hit at least $30 this year.   |
The Motley Fool
May 7, 2004
Mark Mahorney |
WebMD Not a Sure Winner WebMD, providers of online health information, electronic data interchange services and practice management software and services to the healthcare industry, improved slightly during the first quarter, and it looks to be more of the same ahead. |
The Motley Fool
May 7, 2004
Brian Gorman |
CVS Fuels the Drug Debate Thomas Ryan, the CEO of CVS, supports reimporting drugs from Canada before Congress. Drugs from European companies may actually have a greater impact on price. |
Wired
May 2004
Wil McCarthy |
The Doctor Will Freeze You Now How low-temperature surgery could kick-start the cryo game. |
The Motley Fool
May 5, 2004
Charly Travers |
Growing Profits at Connetics A broad product line is leading to sustainable growth for the small drug developer. |
The Motley Fool
May 5, 2004
Brian Gorman |
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas. |
CRM
May 3, 2004
David Myron |
Vertical Focus: Pharmaceutical Firms Find a Spoonful of CRM Helps the Sales Pitch Go Down Ad campaigns create a pull-marketing effect, bringing patients into doctors' offices with product-specific questions. |
CRM
May 2004
Emmy Favilla |
CRM in Action: Inova Tackles Training to Ensure CRM Success Inova Health System, a not-for-profit healthcare system in Northern Virginia, wanted to ensure the success of its CRM system. |
BusinessWeek
May 10, 2004
Louis Lavelle |
How To Groom The Next Boss Mohapatra's ascension at Quest Diagnostics will be the result of a meticulous process in finding and training a chief executive-in-waiting. |
BusinessWeek
May 10, 2004
John Carey |
Drug Prices: A New Covenant? The states' growing negotiating clout with Big Pharma raises crucial questions |
| <Older 1171-1180 Newer> Return to current articles. |
